Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 977

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

Dr Michaela Kotrova speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting the poster she was presenting on acute lymphoblastic leukaemia patients who were treated with CD19-directed immunotherapies.

She explains that by identifying somatic mutations acquired at the time of CD19-negative relapse in patients after blinatumomab treatment, they found CD19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell treatment.

Dr Kotrova explains the next steps to investigating this finding further and the importance of understanding the mechanism of CD-19 loss.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation